January 11, 2020
— Liquid biopsies offer a secure and reliable way to collect samples, to treat invasively and to diagnose more rapidly, resulting in increased demand for these tools. It is a rapid process that usually involves simply drawing blood, extracting nucleic acids from the blood plasma, and amplifying molecular targets to allow the identified biomarkers. Increasing awareness of minimally invasive procedures, favorable government initiatives and the presence of an immense cancer population base are key drivers of market growth. United States Biopsy Market is predicted to surpass USD 14 Billion by the end of the year 2025.
Renub Research report titled “United States Biopsy Market, Volume & Forecast by Segments (Breast, Prostate, Lung, Liver ,Thyroid, Kidney, Colorectal and Skin) Cancer, Companies (C. R. Bard, Inc., Becton, Dickinson and Company, B. Braun Melsungen AG, Cardinal Health, Inc., Olympus Corporation, FUJIFILM Holdings Corporation, Medtronic plc., Hologic, Inc)” provides a complete analysis of the United States Biopsy Market and Volume.
Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=united-states-biopsy-testing-market-and-volume-analysis-to-2020-511-p.php
The major factors that fuel the United States liquid biopsy market are; increasing prevalence of different types of cancer, non-invasive techniques such as liquid biopsy tests are in more demand in United States, comfort of patient, detection of tumor in early stages, rising healthcare infrastructure, increasing per capita income and increasing awareness regarding liquid biopsy in United States.
The key obstacles against United States growth in the market for liquid biopsy are the lack of reimbursements and constantly changing regulations for laboratory-developed tests leading to growing costs of new tests and delays in market availability, low specificity and sensitivity.
Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=united-states-biopsy-testing-market-and-volume-analysis-to-2020-511-p.php
By Segments: Different types of cancer are being examined in this biopsy market; Liver Cancer Biopsy, Thyroid Cancer Biopsy, Kidney Cancer Biopsy, Colorectal Cancer Biopsy, Skin Cancer Biopsy, Lung Cancer Biopsy, Prostate Cancer Biopsy and Breast Cancer Biopsy. This study provides a multi-factorial overview of why the rate of biopsy in the United States is growing by a different type of cancer biopsy test.
By Companies: This report included all top key players analysis; Hologic, Inc, Medtronic plc, FUJIFILM Holdings Corporation, Olympus Corporation, Cardinal Health, Inc., B. Braun Melsungen AG, Becton, Dickinson and Company and C. R. Bard, Inc.
If the information you seek is not included in the current scope of the study kindly share your specific requirements with our custom research team.
Key Topics Covered :
2. Research Methodology
3. Executive Summary
4. United States Biopsy Market & Volume
4.1 Market & Forecast
4.2 Volume & Forecast
5. United States Biopsy Share
5.1 Market Share & Forecast
5.2 Volume Share & Forecast
6. Segment – United States Biopsy Market
6.1 Prostate Cancer Biopsy
6.2 Breast Cancer Biopsy
6.3 Lung Cancer Biopsy
6.4 Liver Cancer Biopsy
6.5 Thyroid Cancer Biopsy
6.6 Kidney Cancer Biopsy
6.7 Colon & Rectum Cancer Biopsy
6.8 Melanoma Skin Cancer Biopsy
7. Company Analysis
7.1 Becton, Dickinson & Company
7.2 B. Braun Melsungen AG (Germany)
7.3 Cardinal Health, Inc.
7.4 Olympus Corporation (Japan)
7.5 Boston Scientific Corporation (U.S.)
7.6 Medtronic Plc.
7.7 Hologic, Inc.
8. Growth Factors
8.1 Inadequate Screening Tests for Particular Cancers
8.2 Demand for Minimally-Invasive Biopsy Techniques
8.3 Advancement in Biopsy Techniques
9.1 Reimbursement Issues
Email: [email protected]